Literature DB >> 19435621

[Digestive oncology: surgical practices].

K Slim1, J Y Blay, A Brouquet, D Chatelain, M Comy, J R Delpero, C Denet, D Elias, J F Fléjou, P Fourquier, D Fuks, O Glehen, M Karoui, N Kohneh-Shahri, M Lesurtel, C Mariette, F Mauvais, J Nicolet, Th Perniceni, G Piessen, J M Regimbeau, Ph Rouanet, A sauvanet, G Schmitt, C Vons, Ph Lasser, J Belghiti, S Berdah, G Champault, L Chiche, J Chipponi, P Chollet, Th De Baère, P Déchelotte, J M Garcier, B Gayet, C Gouillat, R Kianmanesh, C Laurent, C Meyer, B Millat, S Msika, B Nordlinger, F Paraf, C Partensky, F Peschaud, M Pocard, B Sastre, J Y Scoazec, M Scotté, J P Triboulet, H Trillaud, P Valleur.   

Abstract

Mesh：

Year:  2009        PMID： 19435621     DOI： 10.1016/S0021-7697(09)72398-1

Source DB:  PubMed          Journal:  J Chir (Paris)        ISSN： 0021-7697


× No keyword cloud information.
  7 in total

1.  A lymph node ratio of 10% is predictive of survival in stage III colon cancer: a French regional study.

Authors:  Charles Sabbagh; François Mauvais; Cyril Cosse; Lionel Rebibo; Jean-Paul Joly; Didier Dromer; Christine Aubert; Sophie Carton; Bernard Dron; Innocenti Dadamessi; Bernard Maes; Guillaume Perrier; David Manaouil; Jean-François Fontaine; Michel Gozy; Xavier Panis; Pierre Henri Foncelle; Hugues de Fresnoy; Fabien Leroux; Pierre Vaneslander; Caroline Ghighi; Jean-Marc Regimbeau
Journal:  Int Surg       Date:  2014 Jul-Aug

2.  Proximal gastrectomy versus total gastrectomy for proximal third gastric cancer: total gastrectomy is not always necessary.

Authors:  Pavan Sugoor; Sanket Shah; Rohit Dusane; Ashwin Desouza; Mahesh Goel; Shailesh V Shrikhande
Journal:  Langenbecks Arch Surg       Date:  2016-05-04       Impact factor: 3.445

3.  NORAD01-GRECCAR16 multicenter phase III non-inferiority randomized trial comparing preoperative modified FOLFIRINOX without irradiation to radiochemotherapy for resectable locally advanced rectal cancer (intergroup FRENCH-GRECCAR- PRODIGE trial).

Authors:  Antoine Brouquet; Jean-Baptiste Bachet; Florence Huguet; Mehdi Karoui; Pascal Artru; Charles Sabbagh; Jérémie H Lefèvre; Dewi Vernerey; Christophe Mariette; Eric Vicaut; Stephane Benoist
Journal:  BMC Cancer       Date:  2020-05-29       Impact factor: 4.430

4.  Multicenter phase III randomized trial comparing laparoscopy and laparotomy for colon cancer surgery in patients older than 75 years: the CELL study, a Fédération de Recherche en Chirurgie (FRENCH) trial.

Authors:  Gilles Manceau; Antoine Brouquet; Pascal Chaibi; Guillaume Passot; Olivier Bouché; Murielle Mathonnet; Jean-Marc Regimbeau; Rea Lo Dico; Jérémie H Lefèvre; Frédérique Peschaud; Olivier Facy; Enrico Volpin; Elie Chouillard; Laura Beyert-Berjot; Marc Verny; Mehdi Karoui; Stéphane Benoist
Journal:  BMC Cancer       Date:  2019-12-04       Impact factor: 4.430

5.  Postoperative Quality Assessment Score Can Select Patients with High Risk for Locoregional Recurrence in Colon Cancer.

Authors:  Cristian Livadaru; Mihaela Moscalu; Florina Adriana Ghitun; Alexandra Ramona Huluta; Cristina Terinte; Dan Ferariu; Sorinel Lunca; Gabriel Mihail Dimofte
Journal:  Diagnostics (Basel)       Date:  2022-02-01

6.  Phase II/III multicentre randomised controlled trial evaluating a strategy of primary surgery and adjuvant chemotherapy versus peri-operative chemotherapy for resectable gastric signet ring cell adenocarcinomas - PRODIGE 19 - FFCD1103 - ADCI002.

Authors:  Guillaume Piessen; Mathieu Messager; Karine Le Malicot; William B Robb; Frédéric Di Fiore; Marie Guilbert; Marie Moreau; Véronique Christophe; Antoine Adenis; Christophe Mariette
Journal:  BMC Cancer       Date:  2013-06-10       Impact factor: 4.430

7.  Resectable pancreatic adenocarcinoma neo-adjuvant FOLF(IRIN)OX-based chemotherapy - a multicenter, non-comparative, randomized, phase II trial (PANACHE01-PRODIGE48 study).

Authors:  Lilian Schwarz; Dewi Vernerey; Jean-Baptiste Bachet; Jean-Jacques Tuech; Fabienne Portales; Pierre Michel; Antonio Sa Cunha
Journal:  BMC Cancer       Date:  2018-07-24       Impact factor: 4.430
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.